During the last session, Ensysce Biosciences Inc (NASDAQ:ENSC)’s traded shares were 0.41 million, with the beta value of the company hitting 0.85. At the end of the trading day, the stock’s price was $0.18, reflecting an intraday loss of -4.41% or -$0.01. The 52-week high for the ENSC share is $2.06, that puts it down -1044.44 from that peak though still a striking 5.56% gain since the share price plummeted to a 52-week low of $0.17. The company’s market capitalization is $2.47M, and the average intraday trading volume over the past 10 days was 0.35 million shares, and the average trade volume was 1.81 million shares over the past three months.

Ensysce Biosciences Inc (ENSC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ENSC has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.29.

Ensysce Biosciences Inc (NASDAQ:ENSC) trade information

Ensysce Biosciences Inc (ENSC) registered a -4.41% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.41% in intraday trading to $0.18, hitting a weekly high. The stock’s 5-day price performance is -20.45%, and it has moved by -43.56% in 30 days. Based on these gigs, the overall price performance for the year is -85.31%. The short interest in Ensysce Biosciences Inc (NASDAQ:ENSC) is 0.18 million shares and it means that shorts have 0.54 day(s) to cover.

Ensysce Biosciences Inc (ENSC) estimates and forecasts

Statistics show that Ensysce Biosciences Inc has outperformed its competitors in share price, compared to the industry in which it operates. Ensysce Biosciences Inc (ENSC) shares have gone down -76.13% during the last six months, with a year-to-date growth rate more than the industry average at 69.51% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 66.70% this quarter and then jump 81.80% in the quarter after that. In the rating firms’ projections, revenue will decrease -52.90% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 250k as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 240k by the end of current fiscal year.

While earnings are projected to return 76.33% in 2024.

ENSC Dividends

Ensysce Biosciences Inc is due to release its next quarterly earnings on 2024-Nov-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Ensysce Biosciences Inc (NASDAQ:ENSC)’s Major holders

Ensysce Biosciences Inc insiders own 1.54% of total outstanding shares while institutional holders control 4.42%, with the float percentage being 4.48%. PLANTE MORAN FINANCIAL ADVISORS, LLC is the largest shareholder of the company, while 11.0 institutions own stock in it. As of 2024-06-30, the company held over 20.0 shares (or 0.0004% of all shares), a total value of $10.0 in shares.

Also, the Mutual Funds coming in first place with the largest holdings of Ensysce Biosciences Inc (ENSC) shares are Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Aug 31, 2024 indicates that Fidelity Extended Market Index Fund owns about 43.23 shares. This amounts to just over 0.31 percent of the company’s overall shares, with a $7686.0 market value. The same data shows that the other fund manager holds slightly less at 18.18, or about 0.13% of the stock, which is worth about $3231.0.